Video
Lutetium 177 PSMA enhances QOL in patients with mCRPC
Author(s):
"The results of this trial impacted practice globally,” says Michael J. Morris, MD.
Video Player is loading.
In this video, Michael J. Morris, MD, discusses the background, findings, and takeaways of the VISION trial, which was presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Related Content
